Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin and Precision Radiation Therapy in Oligoprogressive NSCLC
NCT03546829Phase 1Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Mar 2019
- Primary completion
- Dec 2027
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vancomycin in non-small cell lung cancer (NSCLC), sponsored by Abramson Cancer Center. Primary endpoints: Th1 immune response measured by cytokine expression (IFN gamma) at 2 years, Safety of the addition of vancomycin to Stereotactic Body Radiotherapy at 2 years and 1 more. Started Mar 2019; status: recruiting.
02
Drugs
vancomycin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03546829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546829.